VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Non-Congress | TCXpress™, a novel promising TCR platform

David Apelian, MD, PhD, BlueSphere Bio, Pittsburgh, PA, highlights the key features and advantages of TCXpress™, a novel T-cell receptor (TCR) platform. TCXpress™ is able to capture, express, and characterize thousands of TCRs targeted to any antigen expressed inside or on the surface of a cancer cell in a very short time. This technology will be used as a platform for discovery and partnering. This interview was recorded virtually.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter